Cortical nonenhancing tumor infiltration: a predictive imaging biomarker for IDH-mutant glioma
Journal of Neurosurgery · 2025
DOI: 10.3171/2024.11.jns242017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurosurgery, 2025. Verfasst von Xijie Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Isocitrate Dehydrogenase. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE The aim of this study was to evaluate the cortical nonenhancing tumor infiltration (CONTIN) sign as a predictive imaging biomarker for IDH-mutant gliomas, including diffuse gliomas with and without contrast enhancement. METHODS Imaging data were collected from patients with diffuse gliomas (grades 2–4) at Beijing Tiantan Hospital (BTH) from January 2019 to December 2021 (training set, n = 526) and from the University of California, San Francisco, preoperative diffuse glioma MRI dataset (UCSF PDGM; validation set, n = 501). Two independent reviewers assessed the CONTIN sign and other radiological features to develop a diagnostic strategy. RESULTS Interrater agreement for the CONTIN sign was almost perfect (κ = 0.812). In the BTH cohort, the prevalence of the CONTIN sign in IDH-mutant gliomas was 90.1% overall, with a rate of 92.2% (106/115) in contrast-enhancing gliomas and 88.9% (168/189) in nonenhancing gliomas. In the UCSF PDGM cohort, the overall prevalence was 85.4%, with 81.4% in contrast-enhancing gliomas and 88.3% in nonenhancing gliomas. In contrast-enhancing gliomas, the CONTIN sign significantly improved sensitivity compared with the T2-FLAIR mismatch (T2FMM) sign, with an increase from 14.8% to 92.2% in the BTH cohort and from 23.3% to 81.4% in the UCSF PDGM cohort. Additionally, the CONTIN sign had a high specificity (82.8% in the BTH cohort, 87.4% in the UCSF PDGM cohort) and negative predictive value (94.6% in the BTH cohort, 97.6% in the UCSF PDGM cohort). By integrating the CONTIN sign with T2FMM, contrast enhancement, age at diagnosis, and other features, a reliable diagnostic protocol for IDH-mutant gliomas was established. CONCLUSIONS The CONTIN sign was a robust imaging biomarker for identifying IDH mutation status in diffuse glioma, particularly for those with contrast enhancement. Preoperative knowledge of IDH mutation status can enhance patient counseling and inform treatment decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing.
- 2Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing.
- 3Department of Neurosurgery, China-Japan Friendship Hospital, Beijing; and.
- 4National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders and Beijing Key Laboratory of Brain Tumor, Beijing, China.
Zitieren
APA
Wang, X., Jiang, H., Li, M., Zhang, X., Li, H., Li, M., Ren, X., Zhang, S., Tong, S., Liu, A., Ren, Q., Cui, Y., & Lin, S. (2025). Cortical nonenhancing tumor infiltration: a predictive imaging biomarker for IDH-mutant glioma. Journal of Neurosurgery. https://doi.org/10.3171/2024.11.jns242017
Vancouver
Wang X, Jiang H, Li M, Zhang X, Li H, Li M, et al. Cortical nonenhancing tumor infiltration: a predictive imaging biomarker for IDH-mutant glioma. Journal of Neurosurgery. 2025. doi:10.3171/2024.11.jns242017
BibTeX
@article{Wang2025,
author = {Wang, Xijie and Jiang, Haihui and Li, Mingxiao and Zhang, Xiaokang and Li, Haoyi and Li, Ming and Ren, Xiaohui and Zhang, Shouzan and Tong, Siqi and Liu, Anzhu and Ren, Qingsen and Cui, Yong and Lin, Song},
title = {Cortical nonenhancing tumor infiltration: a predictive imaging biomarker for IDH-mutant glioma},
journal = {Journal of Neurosurgery},
year = {2025},
doi = {10.3171/2024.11.jns242017}
}
EUVIMED